New Developments in the Technique of Partial Nephrectomy
Friday, 01 September 2006
BERKELEY, CA (UroToday.com) - While partial nephrectomy has demonstrated oncologic equipoise with radical nephrectomy, it remains a surgically daunting procedure that can be associated with significant complications, particularly related to hemostasis and prevention of post-operative urinary fistulae.
read more
|
Circulating Tumor Cells in the Peripheral Blood of Patients with Renal Cell Carcinoma: RT-PCR Assays for Carbonic Anhydrase IX Expression Predict Risk of Disease Recurrence
Thursday, 31 August 2006
BERKELEY, CA (UroToday.com) - Investigations in a variety of tumor types have demonstrated that circulating tumor cells are present in the peripheral blood of patients, even those with what is thought to be otherwise localized disease, and can be prognostic of outcome.
read more
|
Tumor Specific Tissue Markers in Renal Cell Carcinoma: Kidney Specific Cadherin Falls Short of the Mark
Tuesday, 29 August 2006
BERKELEY, CA (UroToday.com) - The frequent inability to differentiate oncocytoma from chromophobe renal cell carcinoma (chRCC) from renal tumor biopsy material remains a large impediment to the increased utilization of renal tumor biopsy.
read more
|
Allogeneic Bone Marrow Transplantation For Metastatic Renal Cell Carcinoma: The European Experience
Monday, 28 August 2006
BERKELEY, CA (UroToday.com) - Allogeneic bone marrow transplantation is yet another treatment option for patients with metastatic renal cell carcinoma (mRCC), where initial reports by Childs out of the National Cancer Institute demonstrated significant disease responses.
read more
|
Comparing the Outcomes of Elective Partial to Radical Nephrectomy in Clear Cell Renal Cell Carcinoma 4-7 cm in Diameter
Thursday, 24 August 2006
BERKELEY, CA (UroToday.com) - In this report out of MSKCC, the authors report on 196 patients that underwent renal surgery for clear cell renal cell carcinoma (ccRCC) that measured 4-7 cm in diameter.
read more
|
24th WCE 2006 - Poster Session VP4
Wednesday, 23 August 2006
This video poster section contained 25 abstracts with highlighted topics such as the percutaneous management of uretropelvic junction obstruction (UPJO), ureteroscopic management of upper tract transitional cell carcinoma (UTTCC) and stone disease, These video posters were as eclectic as they were outstanding.
read more
|
Identifying the Molecular Mechanisms Behind the Invasive Phenotype in Renal Cell Carcinoma
Tuesday, 22 August 2006
BERKELEY, CA (UroToday.com) - Advances in new therapies for renal cell carcinoma (RCC) have come about as a consequence of a further understanding of the biology associated with local progression and metastasis.
read more
|
Does Involvement of the Collecting System by Energy Ablation Techniques Used to Treat Small Renal Masses Increase the Risk of Post-Procedural Complications?
Monday, 21 August 2006
BERKELEY, CA (UroToday.com) - Energy ablative strategies (percutaneous and laparoscopic) are being increasingly employed in the treatment of small renal masses.
read more
|
Laparoscopic Partial Nephrectomy Using the Potassium Titnyl Phosphate Laser in a Porcine Model
Monday, 21 August 2006
BERKELEY, CA (UroToday.com) - Working with an 80 watt KTP laser delivered in a noncontact mode via a 600 micron fiber, these authors successfully completed 15 laparoscopic partial nephrectomies in pigs. This was done without clamping any renal vessels.
read more
|
Survivin: A Tissue Marker of Poor Prognosis in Clear Cell Renal Cell Carcinoma
Friday, 18 August 2006
BERKELEY, CA (UroToday.com) - The search for molecular markers that further advance our knowledge of the biology of renal cell carcinoma (RCC) and assist in evaluating the diagnosis and prognosis of patients remains the subject of intense investigation.
read more
|
Collecting Duct Carcinoma: The Japanese Experience
Thursday, 17 August 2006
BERKELEY, CA (UroToday.com) - Collecting duct carcinoma is a rare and highly aggressive variant of renal cell carcinoma that frequently presents with advanced disease, has few effective treatment options, and is associated with a poor prognosis.
read more
|
Trying to Improve on the Activity of Interferon-Alpha in Metastatic Renal Cell Carcinoma: Interferon Plus Cimetidine in a Phase III Randomized Trial
Wednesday, 16 August 2006
BERKELEY, CA (UroToday.com) - - Interferon-alpha (IFN) has been a mainstay in the systemic treatment of metastatic renal cell carcinoma (RCC) for decades, with response rates ranging from 3-15%.
read more
|
Infiltration Of Renal Cell Carcinoma Primary Tumors By Mononuclear Cells Portends A Poor Prognosis
Friday, 11 August 2006
BERKELEY, CA (UroToday.com) - Renal cell carcinoma (RCC) has long been recognized to be an immunologically relevant tumor in part due to the histologic observation that immune cells are frequently found to infiltrate resected primary tumors.
read more
|
Size Doesn’t Matter!!! Size of a Negative Margin of Resection in Partial Nephrectomy has no Bearing on Patient Outcome
Wednesday, 09 August 2006
BERKELEY, CA (UroToday.com) - Traditional oncology dogma dictates that margins of resection are critical correlates to patient outcome.
read more
|
Novel Approaches To Metastatic Renal Cell Carcinoma: Autologous Thymocytes Genetically Retargeted Against Carbonic Anhydrase IX
Tuesday, 08 August 2006
BERKELEY, CA (UroToday.com) - In this letter to the editor, Lamers and colleagues out of the Netherlands describe their initial experience with genetically retargeted autologous lymphocytes directed against carbonic anhydrase IX (CA9).
read more
|
European Commission Grants Conditional Marketing Authorization To Pfizer’s Sutent®
Monday, 07 August 2006
BERKELEY, CA (UroToday.com) - Pfizer Inc said today that Sutent® (sunitinib malate) has received European conditional marketing authorization for advanced and/or metastatic renal cell carcinoma (mRCC), a type of advanced kidney cancer, after failure of interferon alfa and interleukin-2 therapies.
read more
|
Relationship Between Patient Age and the Clinical Characteristics of Renal Cell Carcinoma
Friday, 04 August 2006
BERKELEY, CA (UroToday.com) - Recent studies have suggested a relationship between age and the clinical characteristics of renal cell carcinoma (RCC), where the biology of tumors in younger patients may be quite different from that found in older patients.
read more
|
B7-H1 Tumor Expression is a Marker of Prognosis in Renal Cell Carcinoma
Wednesday, 02 August 2006
BERKELEY, CA (UroToday.com) - UroToday.com - B7-H1 is a tumor associated antigen that participates in T-cell costimulation as a negative regulator of immunity. Tumor expression of this antigen has been shown to be associated with a worse prognosis in renal cell carcinoma (RCC).
read more
|
Is Renal Capsular Invasion, without Perinephric Fat Invasion, a Marker of Aggressive Biology in Renal Cell Carcinoma?
Tuesday, 01 August 2006
BERKELEY, CA (UroToday.com) - Perinephric fat invasion is an accepted pathologic marker of aggressive biology in renal cell carcinoma (RCC). Renal capsule invasion, without perinephric fat invasion, is often reported in pathology reports but is not accounted for in current TNM staging as a distinct classification that differentiates outcome.
read more
|
BJUI Mini Reviews - Minimally Invasive Nephron-Sparing Surgery for Renal Cell Cancer
Tuesday, 01 August 2006
In this review, we examine the principles of MINSS, the salient technical aspects of the procedures, the current results to date, and future concepts.
Login to read more...
|
Defining the Molecular Correlates for the Presence of “Symptomatic” Primary Tumors in Renal Cell Carcinoma
Friday, 28 July 2006
BERKELEY, CA (UroToday.com) - The presence of symptoms (pain, hematuria, systemic malaise, fever, weight loss, etc.) associated with a primary renal cell carcinoma (RCC) tumor has been shown to be a poor prognostic feature in patients with localized disease.
read more
|
Treatment Of Locally Recurrent Renal Cell Carcinoma
Thursday, 27 July 2006
BERKELEY, CA (UroToday.com) - Local recurrence of renal cell carcinoma (RCC) is extremely rare, occurring in less than 2% of patients, with distant metastatic progression far more common.
read more
|
Nexavar® Approved by European Commission for the Treatment of Advanced Kidney Cancer
Wednesday, 26 July 2006
West Haven, CT and Emeryville, CA – Bayer Pharmaceuticals Corporation (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the European Commission has granted marketing authorization to Nexavar® (sorafenib) tablets for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy. Bayer will commercialize Nexavar in Europe.
read more
|
√ Sunitinib in Patients with Metastatic Renal Cell Carcinoma
Monday, 24 July 2006
√ Editor's Pick: BERKELEY, CA (UroToday.com) - The treatment of advanced renal cell carcinoma [RCC] is undergoing a paradigm shift with the recent introduction of anti-angiogenic therapy that either directly inhibits vascular endothelial growth factor or disrupts signal transduction favorable to vascular development through multi-kinase inhibitors.
read more
|
Overtreatment of Localized Renal Cell Carcinoma: Are We Over Utilizing Developing Technologies Rather Than Letting Disease Biology Dictate Appropriate Treatment?
Friday, 21 July 2006
BERKELEY, CA (UroToday.com) - Recently published studies based on SEER database analyses have suggested that nephron sparing approaches are being vastly underutilized in the surgical treatment of small renal masses.
read more
|
√ Sorafenib In Renal Cell Carcinoma: Results Of the Phase II Placebo-Controlled Randomized Discontinuation Trial
Wednesday, 19 July 2006
√ Editor's Pick: BERKELEY, CA (UroToday.com) - Sorafenib was recently approved by the FDA as a systemic therapy option for metastatic renal cell carcinoma (RCC) in part due to the data from this phase II placebo-controlled randomized discontinuation trial.
read more
|
Differentiating Chromophobe Renal Cell Carcinoma From Oncocytoma Remains A Diagnostic Dilemma That Hampers The Utility Of Renal Mass Biopsy: Contribution Of Caveolin-1 Immunohistochemistry
Thursday, 13 July 2006
BERKELEY, CA (UroToday.com) - The Achille's heel that continues to plague the utility of renal biopsy in the evaluation of renal masses is the reliable differentiation of chromophobe renal cell carcinoma (malignant) from oncocytoma (benign).
read more
|
Urologic Professionals to Learn Latest Practice Advances at Society of Urologic Nurses and Associates Annual Conference
Monday, 10 July 2006
Pitman, NJ - The Society of Urologic Nurses and Associates' (SUNA) will hold its 2006 Annual Conference in Kansas City, MO, October 27-30, 2006, at the Hyatt Regency Crown Center.
read more
|
Phase I Trial Of Carbonic Anhydrase IX (CA9) Peptide Vaccine In Cytokine Refractory Metastatic Renal Cell Carcinoma
Friday, 30 June 2006
BERKELEY, CA (UroToday.com) - CA9 is a tumor associated antigen that is expressed on the majority of renal cell carcinomas (RCC's) as well as other tumors. As a consequence of this finding, several therapeutic strategies have been developed that target CA9, including monoclonal antibody therapy, genetically engineered autologous T cells, and others. Here, Uemura and colleagues report on a vaccine strategy targeting CA9 through the use of CA9 peptides in combination with Freund's adjuvant in cytokine refractory RCC out of Japan.
read more
|
Intermediate Results Of Laparoscopic Cryoablation In 59 Patients At The Medical College Of Wisconsin
Wednesday, 21 June 2006
BERKELEY, CA (UroToday.com) - Among 81 renal tumors in 59 patients, laparoscopic cryoablation was successful in 97.5% at 2.3 years follow-up. The authors did the procedure under control with a laparoscopic ultrasound probe using 5 mm cryoprobes; average lesion size was 2.5 cm. If one limits results to only patients with proven renal cancer, then the success rate would be 94% among 34 patients.
read more
|
Renal Cell Carcinoma In The Pediatric Population
Friday, 16 June 2006
BERKELEY, CA (UroToday.com) - While the incidence of renal cell carcinoma (RCC) is rising, it remains a relatively uncommon malignancy in the pediatric population, where it represents only 2-6% of solid renal malignancies. In this report, Cook and colleagues describe their experience with the management of RCC in childhood, specifically examining the role of partial nephrectomy as a reasonable surgical approach in patients with anatomically amenable tumors.
read more
|
Validation Of The Mayo SSIGN Score As A Prognostic Nomogram In Conventional (Clear Cell) Renal Cell Carcinoma
Thursday, 15 June 2006
BERKELEY, CA (UroToday.com) - Several prognostic nomograms exist to assess the outcome of patients with renal cell carcinoma (RCC). These include the UISS out of UCLA, the Kattan nomogram out of Memorial Sloan-Kettering, and the SSIGN score out of Mayo. A criticism of these and other nomograms is that they are modeled and validated on a single population of patients and may lack the versatility to be extrapolated to other patient samples. Recently, the UISS was externally validated in a multi-institutional dataset that proved its value as a prognostic aid in patients with RCC. Here Ficarra and colleagues, out of the University of Verona in Italy, externally validate the Mayo SSIGN score system.
read more
|
Nexavar Receives Fast Track Designation from the FDA for Metastatic Liver Cancer
Tuesday, 13 June 2006
Bayer Pharmaceuticals Corporation (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced today that Nexavar® (sorafenib) tablets has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic hepatocellular carcinoma (HCC), or liver cancer. Nexavar was approved by the FDA in December 2005 for the treatment of patients with advanced renal cell carcinoma (RCC).
read more
|
Is There An Increased Risk Of Other Malignancies In Patients With Renal Cell Carcinoma?
Monday, 12 June 2006
BERKELEY, CA (UroToday.com) - There have been conflicting reports in the literature regarding the association of other malignancies with renal cell carcinoma (RCC). In this study by Beisland and colleagues, out of Norway, the association of RCC with other malignancies is again examined.
read more
|
ASCO 2006 - GU Oral Presentation Renal Cancer
Friday, 09 June 2006
Sunitinib and sorafenib, oral multi-targeted tyrosine kinase inhibitors of the VEGF receptor and PDGF receptor, are approved by the US FDA for the treatment of metastatic RCC. In the ASCO plenary session, Motzer et al. presented a phase III randomized trial comparing sunitinib with interferon-alfa as first line therapy for patients with metastatic Renal cell cancer. This trial demonstrated a significant improvement in progression-free survival in the sunitinib arm. At the oral GU session, two abstracts further our understanding of the role of the oral multi-targeted tyrosine kinase inhibitors of the VEGF receptor and PDGF receptor in the management of metastatic RCC.
read more
|
ASCO 2006 - Plenary Session: Renal Cell Cancer
Tuesday, 06 June 2006
The treatment of patients with metastatic renal cell carcinoma has relied upon the use of cytokine therapy such as interferon-alfa or interleukin-2. These treatments resulted in a minority of patients benefiting. While a small proportion of highly selected patients have derived long-term benefit from cytokine therapy, most do not. The median survival of patients with metastatic renal cell cancer treated with IFN-alfa is 4 – 6 months. Recently, promising results of targeted therapy for patients with metastatic renal cell cancer have been reported. Both surafenib and sunitimib, oral multitargeted inhibitors of VEGF and PDGF receptors, have demonstrated efficacy in the second-line setting, resulting in FDA approval. Two studies of targeted therapy in the first-line setting for patients with metastatic renal cell cancer were reported at the June 4, 2006 ASCO Plenary session.
read more
|
BJUI Mini Reviews - Anaemia in the Critically Ill Patient: Monitoring of Erythropoietin Therapy
Thursday, 01 June 2006
In this article we discuss some of these key issues from specific studies with the aim of answering the following questions: (i) For which of the critically ill patients is the administration of rHuEPO a therapeutic option? (ii) Which biochemical serum markers and haematological blood cell indices predict an early response to rHuEPO administration, and indicate iron demand in the bone marrow? (iii) Is it possible to use a predictive model which can be used to adequately monitor rHuEPO response and FID?
Login to read more...
|
AUA 2006 - BIOGLUE®: Moving Toward A Surtureless Partial Nephrectomy
Wednesday, 24 May 2006
Berger, AD et al., New York, NY
V1214
read more
|
AUA 2006 - Laparoscopic Partial Nephrectomy For Multiple Renal Tumors
Wednesday, 24 May 2006
Vira, MA et al., Bethesda, MD
V1213
read more
|
AUA 2006 - The Impact Of Lymphadenectomy At The Time Of Nephrectomy For Metastatic RCC
Wednesday, 24 May 2006
Leibovich, BC et al., Rochester, MN
Abstract 1115
read more
|
AUA 2006 - A Comparison Of Nephron-Sparing Techniques: Percutaneous Radiofrequency Ablation (RFA) VS. Open And Laparoscopic Partial Nephrectomy
Wednesday, 24 May 2006
Feldman AS, et al., Boston, MA
Abstract 1114
read more
|
AUA 2006 - Stage Migration In Renal Cell Carcinoma Patients Demonstrated By Analysis Of The National Cancer Database
Wednesday, 24 May 2006
1993-2003. Kane CJ, et al., San Francisco, CA.
Abstract 1105
read more
|
AUA 2006 - Prognostic Factors And Long-Term Outcome Following Resection Of Renal Cell Carcinoma With Right Atrial Extension:Impact On Survival And Benefits Of Immunotherapy
Wednesday, 24 May 2006
Lam, JS et al., Los Angeles, CA
Abstract 1099
read more
|
AUA 2006 - Metachronous Contralateral Renal Cell Carcinoma: Influence Of Race And Tumor Histology
Wednesday, 24 May 2006
Kwon, EO, et al., New York, NY
Abstract 1097
read more
|
AUA 2006 - Association Of Abnormal Preoperative Laboratory Values With Survival Following Radical Nephrectomy For Clinically Confined
Wednesday, 24 May 2006
Magera, JS, Rochester, MN.
Abstract 1095
read more
|
AUA 2006 - Point-Counterpoint Debate On “Should A Small Renal Lesion Be Monitored Or Ablated”
Wednesday, 24 May 2006
Dr. S. Larry Goldenberg, University of British Columbia moderated a debate on "Should a Small Renal Lesion be Monitored or Ablated" at the plenary session of the AUA on Tuesday May 23, 2006.
read more
|
AUA 2006 - Renal Cryoablation: 5 Year Outcomes
Wednesday, 24 May 2006
Hegarty, NJ, et al., Cleveland, OH.
Abstract 1091
read more
|
AUA 2006 - Separation Of Chromphobe Renal Cell Carcinoma From Oncocytoma And Clear Cell Carcinoma: An Otimal Immunohistochemical
Wednesday, 24 May 2006
Liu, L, et al, Glen Allen, VA
Abstract 1088
read more
|
AUA 2006 - Kidney and Ureteral Cancer: Basic Research Discussed Poster Session 6
Tuesday, 23 May 2006
This session represented several abstracts dealing with the molecular pathology of renal cell carcinoma as well as investigations directed towards identifying novel tumor markers of progression and outcome in renal cell carcinoma.
read more
|
AUA 2006 - Immune Mediated Survival Advantage And Primary Tumor Control Of Cryoablation Compared To Nephrectomy In A Murine Model Of Advanced Renal Cancer
Tuesday, 23 May 2006
Hedican, SP, et al., Madison, WI
Abstract 404
An interesting study by Hedican and colleagues suggests that energy ablative therapies such as cryoablation may offer more than just local tumor control, by augmenting host immune function, to improve survival.
read more
|
Renal Cancer 
